Bayer healthcare participation..........

iVillage Member
Registered: 10-19-2005
Bayer healthcare participation..........
Thu, 02-23-2006 - 4:15pm



Successful Bayer HealthCare participation in the European Society of Cardiology Congress 2005



The recent European Society of Cardiology (ESC) congress in Stockholm, Sweden, was a great success for Bayer HealthCare, with two very well-attended satellite programmes. The Aspirin symposium was held on the first day of the congress and around 420 delegates attended to hear the experts review the Evolving evidence of Aspirin therapy: which populations, which doses. Two renowned cardiologists, Professors Freek Verheugt and Charles Hennekens were excellent chairmen, opening the symposium with the remark that Aspirin is "the most fascinating drug cardiology has ever seen" and closing the meeting on a positive note reminding the audience that "Aspirin was the wonder drug of the 20th century and may well be the wonder drug of the 21st century."

Professor Lars Ryden co-chaired an exciting case-study-based programme The cardiovascular disease prevention map - a multiroute approach. Specialists from different fields in cardiovascular disease (CVD) discussed the evidence for benefits of multiple risk assessment and management strategies, focusing on integrated therapy with Adalat, Aspirin and Glucobay. Despite competition from 16 other satellites running at the same time, the Bayer CV Risk Management satellite was attended by around 270 delegates.

Additionally in an ESC press conference Bayer HealthCare and the World Heart Federation (WHF) announced a three-year partnership agreement focusing on the prevention of CVD, the highest cause of death across the world. The announcement demonstrates the organisations' shared commitment to helping the global population achieve a longer and better life through the prevention and control of heart disease and stroke. The conference was held by a high-class faculty consisting amongst others of Valentin Fuster, President of the World Heart Federation and Wolfgang Plischke, President of the Pharmaceuticals Division, Bayer HealthCare.

As always, the Bayer Cardiovascular Risk Products booth had a continuous stream of visitors. Delegates were drawn in by the latest Adalat/ACTION publications, the Aspirin Women's Health Study booklet and Glucobay papers highlighting acarbose as first-line therapy for type 2 diabetes offering additional benefits in CV risk patients.
Image hosted by Photobucket.com
Image hosted by Photobucket.com